A Phase 4 interventional study of Fingolimod and Standard MS DMTs in Relapsing Forms of Multiple Sclerosis, sponsored by Novartis Pharmaceuticals. Completed at 149 sites in 3 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-02-10.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing fingolimod in Multiple Sclerosis — 2 open to participants now, 4 under way, 3 of them phase 3. fingolimod · Multiple Sclerosis.
Among the 34 studies testing fingolimod in Multiple Sclerosis, this one is the 7th largest by enrollment, is one of 4 that started in 2010, is one of 17 in phase 4, and was the 10th registered.
3,271 studies on the registry are indexed under Multiple Sclerosis; 663 are open to participants now.
Browse Multiple Sclerosis studies →2 of the 34 studies testing fingolimod in Multiple Sclerosis are open now, in 3 countries. Recruiting first, the newest first:
TG Therapeutics, Inc. · Sites in United States, Poland, Slovakia
Ages 10–17
Biogen
Ages 10–17
By country, each count listing its studies:
fingolimod: first FDA approval 2010 (GILENYA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 431 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 212 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 13 · Phase 4 17
First in 2003; this study’s year is marked. 4 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,053 is above the median of 50 across 2,205 interventional studies indexed under Multiple Sclerosis.
Median enrollment 167 across the 34 interventional studies. Of the 28 that completed or were terminated, 23 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 34 have an industry lead sponsor. The 6 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
106 studies in Multiple Sclerosis by Novartis: 9 open now, 24 under way, 6 of them phase 3. Of 78 finished, 45 (58%) have results posted.
Among the 106 studies in Multiple Sclerosis by Novartis, this one is the 9th largest by enrollment of the 64 interventional ones that give a count, is one of 6 that started in 2010, is one of 26 in phase 4, and was the 14th registered.
Novartis’s Multiple Sclerosis studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 34 studies testing fingolimod in Multiple Sclerosis, from their registry updates:
Among Novartis’s 106 in Multiple Sclerosis:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the change in patient-reported outcomes, physician assessment of a change as well as safety and tolerability in patients with Relapsing Forms of Multiple Sclerosis on previous Disease Modifying Therapy (DMT) who are randomized to one of two treatment arms: fingolimod vs. standard of care DMT.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria applied
Patients randomized in this arm received Fingolimod 0.5 mg/day oral capsule for 6 months core period .
Drug: Fingolimod
Patients randomized in this arm received selected Standard MS DMT such as Interferon beta-1b or Interferon beta-1a or Glatiramer acetate for 6 months. An open-label extension of up to 3 months of treatment with fingolimod was to be available for patients in the DMT arm who successfully completed all study visits.
Drug: Standard MS DMTs
0.5 mg/day oral capsule
Also known as: GILENYA™
Also known as: Avonex®,, Copaxone®,, Rebif®,, Betaseron®,, Extavia®
Change From Baseline in the Global Satisfaction Subscale of the Treatment Satisfaction Questionnaire for Medication (TSQM) at Month 6
The TSQM was developed and validated as a general measure for treatment satisfaction. It contains 14 items assessing the following 4 domains: effectiveness (sum of scores for questions 1 - 3), side effects (sum of scores for questions 4 - 8), convenience (sum of scores for questions 9 - 11) and Global Satisfaction (sum of scores for questions 12 - 14). The primary analysis was on Global Satisfaction. Question 12 scored as 1(not at all confident) to 5 (extremely confident); question 13 scored as 1(not at all certain) to 5(extremely certain); and question 14 scored as 1(extremely dissatisfied) to 7(extremely satisfied). The scores of the domain were added together and an algorithm was used to create a score of 0 to 100. Higher scores indicated greater satisfaction. A positive change from baseline indicates improvement.
Time frame: Baseline, Month 6
Number of Patients Who Experienced Adverse Events, Serious Adverse Events and Death
In this analysis, patients with all (serious and non-serious) adverse events, serious adverse events and death were reported.
Time frame: 9 months (6 month core + 3 month Extension)
Change From Baseline in Patient-reported Activities of Daily Living (ADL) Using the Multiple Sclerosis Activities Scale (PRIMUS-Activities) at Month 6
The PRIMUS activity measure is a 15-item assessment of patient-reported ADL. The PRIMUS-Activities total score was calculated by summing the 15 item scores after recoding the responses from 1 - 3 to 0 - 2. Totals scores range from 0 to 30 with higher scores indicating greater activity limitation. If no more than 20% of the items were missing, the total score was the product of the mean response of the non-missing items and the total number of items. If more than 20% of all items were missing, the total score was set to missing. A negative change from baseline indicates improvement.
Time frame: Baseline, Month 6
Change From Baseline in Patient-reported Fatigue Using the Fatigue Severity Scale (FSS)
The Fatigue Severity Scale (FSS) is a 9-item assessment scale measuring fatigue and its effects, using a scale from 1 to 7, with higher scores indicating greater fatigue, or greater negative effects of fatigue on daily living. The FSS 9 item total score was calculated by summing the first 9 item scores and dividing by the number of non-missing items. If no more than 20% of the items were missing, the total score was the product of the mean response of the non missing items and the total number of items. If more than 20% of all items were missing, the total score was set to missing. A negative change from baseline indicates improvement.
Time frame: Baseline, Month 3, Month 6
Change From Baseline in the Patient-reported Effectiveness Subscale Using the TSQM v1.4
The effectiveness scale was scored as follows: 1(extremely dissatisfied) to 7(extremely satisfied). The scores of the domain were added together and an algorithm was used to create a score of 0 to 100. Higher scores indicated greater satisfaction. A positive change from baseline indicates improvement.
Time frame: Baseline, Month 6
Change From Baseline in the Patient-reported Side Effects Subscale Using the TSQM v1.4
The Side Effects subscale was scored as follows: question 4 scored as 0(no) or 1(yes); question 5 scored as 1(extremely bothersome) to 5(not at all bothersome); and questions 6 - 8 scored as 1(a great deal) to 5(not at all). The scores of the domain were added together and an algorithm was used to create a score of 0 to 100. Higher scores indicated greater satisfaction. A positive change from baseline indicates improvement.
Time frame: Baseline, Month 6
Change From Baseline in the Patient-reported Convenience Subscale Using the TSQM v1.4
The convenience subscale was scored as follows: questions 9 and 10 scored as 1(extremely difficult) to 7 (extremely easy), and question 11 scored as 1(extremely inconvenient) to 7 (extremely convenient). The scores of the domain were added together and an algorithm was used to create a score of 0 to 100. Higher scores indicated greater satisfaction. A positive change from baseline indicates improvement.
Time frame: Baseline, Month 6
Change From Baseline in Patient-reported Health-related Quality-of-life Using the Short Form Health Survey v2 Standard (SF-36 v2)
The SF-36v2 is a validated health-related quality of life instrument used in numerous disease states, including MS. It is a self-administered survey that measures 8 domains of health including: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems and general mental health. Additionally, two summary scale scores can be calculated: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). If half or more questions within a domain were answered, then a score was calculated for that domain. Otherwise, the patient score for that domain was set to missing. If the patient was missing any 1 of the 8 scale scores, then the physical and mental component scores were set to missing. An algorithm was used to create a score from 0 to 100 for each domain score and component score. A positive change from baseline indicates improvement.
Time frame: Baseline, Month 6
Change From Baseline in Patient-reported Depression Using the Beck Depression Inventory (BDI-II)
The Beck Depression Inventory (BDI-II) is a 21-question multiple-choice self-report inventory. Each item is scored from 0 to 3. The questions in the BDI-II refer to how the patient has been feeling over the past two weeks specifically. The BDI-II total score was calculated by summing the 21 item scores. Final scores ranged from 0 to 63 where higher scores indicated more severe depression. If no more than 20% of the items were missing, the total score was the product of the mean response of the non-missing items and the total number of items. If more than 20% of all items were missing, the total score was set to missing. A negative change indicates improvement.
Time frame: Baseline, Month 3, Month 6
Physician-reported Clinical Global Impression of Improvement (CGI-I)
The CGI-I is a rating scale allowing a physician-reported global evaluation of the subject's improvement over time. The Investigator assessed the subject's clinical change relative to the symptoms at baseline on the CGI-I, a seven-point scale, with rating as follows: 1=Very much improved, 2=Much improved, 3=Minimally improved, 4=No change, 5=Minimally worse, 6=Much worse, 7=Very much worse. The assessments were completed at Month 3 and Month 6. A lower score indicates improvement.
Time frame: Month 3, Month 6
| Milestone | Fingolimod | Multiple Sclerosis Disease Modifying Treatments (MS DMTs) |
|---|---|---|
| Started | 790 | 263 |
| Full analysis set | 789 | 263 |
| Safety set | 783 | 245 |
| Completed | 714 | 229 |
| Not completed | 76 | 34 |
| Withdrew: Adverse event | 40 | 4 |
| Withdrew: Abnormal laboratory value(s) | 2 | 0 |
| Withdrew: Abnormal test procedure result(s) | 3 | 0 |
| Withdrew: Lack of efficacy | 3 | 4 |
| Withdrew: Withdrawal by subject | 12 | 22 |
| Withdrew: Lost to follow-up | 5 | 0 |
| Withdrew: Protocol deviation | 11 | 4 |
| Milestone | Fingolimod | Multiple Sclerosis Disease Modifying Treatments (MS DMTs) |
|---|---|---|
| Started | 0 | 195 |
| Safety set | 0 | 193 |
| Completed | 0 | 181 |
| Not completed | 0 | 14 |
| Withdrew: Adverse event | 0 | 10 |
| Withdrew: Abnormal test procedure results | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 3 |
The TSQM was developed and validated as a general measure for treatment satisfaction. It contains 14 items assessing the following 4 domains: effectiveness (sum of scores for questions 1 - 3), side effects (sum of scores for questions 4 - 8), convenience (sum of scores for questions 9 - 11) and Global Satisfaction (sum of scores for questions 12 - 14). The primary analysis was on Global Satisfaction. Question 12 scored as 1(not at all confident) to 5 (extremely confident); question 13 scored as 1(not at all certain) to 5(extremely certain); and question 14 scored as 1(extremely dissatisfied) to 7(extremely satisfied). The scores of the domain were added together and an algorithm was used to create a score of 0 to 100. Higher scores indicated greater satisfaction. A positive change from baseline indicates improvement.
| units on a scale | Fingolimod | Multiple Sclerosis Disease Modifying Treatments (MS DMTs) |
|---|---|---|
| Change From Baseline in the Global Satisfaction Subscale of the Treatment Satisfaction Questionnaire for Medication (TSQM) at Month 6 | 22.5 ± 27.1 | 3.5 ± 20.57 |
In this analysis, patients with all (serious and non-serious) adverse events, serious adverse events and death were reported.
| Participants | Fingolimod | Multiple Sclerosis Disease Modifying Treatments (MS DMTs) | Extension Fingolimod Period |
|---|---|---|---|
| Adverse Events (serious and non-serious) | 617 | 152 | 123 |
| Serious Adverse Events | 31 | 5 | 7 |
| Death | 0 | 0 | 0 |
The PRIMUS activity measure is a 15-item assessment of patient-reported ADL. The PRIMUS-Activities total score was calculated by summing the 15 item scores after recoding the responses from 1 - 3 to 0 - 2. Totals scores range from 0 to 30 with higher scores indicating greater activity limitation. If no more than 20% of the items were missing, the total score was the product of the mean response of the non-missing items and the total number of items. If more than 20% of all items were missing, the total score was set to missing. A negative change from baseline indicates improvement.
| units on a scale | Fingolimod | Multiple Sclerosis Disease Modifying Treatments (MS DMTs) |
|---|---|---|
| Change From Baseline in Patient-reported Activities of Daily Living (ADL) Using the Multiple Sclerosis Activities Scale (PRIMUS-Activities) at Month 6 | -0.6 ± 4.51 | -0.2 ± 4.97 |
The Fatigue Severity Scale (FSS) is a 9-item assessment scale measuring fatigue and its effects, using a scale from 1 to 7, with higher scores indicating greater fatigue, or greater negative effects of fatigue on daily living. The FSS 9 item total score was calculated by summing the first 9 item scores and dividing by the number of non-missing items. If no more than 20% of the items were missing, the total score was the product of the mean response of the non missing items and the total number of items. If more than 20% of all items were missing, the total score was set to missing. A negative change from baseline indicates improvement.
| units on a scale | Fingolimod | Multiple Sclerosis Disease Modifying Treatments (MS DMTs) |
|---|---|---|
| Change from Baseline to Month 3 (n=710,232) | -0.3 ± 1.24 | 0.0 ± 1.14 |
| Change from Baseline to Month 6 (n=687,218) | -0.4 ± 1.24 | 0.0 ± 1.13 |
The effectiveness scale was scored as follows: 1(extremely dissatisfied) to 7(extremely satisfied). The scores of the domain were added together and an algorithm was used to create a score of 0 to 100. Higher scores indicated greater satisfaction. A positive change from baseline indicates improvement.
| units on a scale | Fingolimod | Multiple Sclerosis Disease Modifying Treatments (MS DMTs) |
|---|---|---|
| Change From Baseline in the Patient-reported Effectiveness Subscale Using the TSQM v1.4 | 15.5 ± 27.53 | 2.8 ± 19.05 |
The Side Effects subscale was scored as follows: question 4 scored as 0(no) or 1(yes); question 5 scored as 1(extremely bothersome) to 5(not at all bothersome); and questions 6 - 8 scored as 1(a great deal) to 5(not at all). The scores of the domain were added together and an algorithm was used to create a score of 0 to 100. Higher scores indicated greater satisfaction. A positive change from baseline indicates improvement.
| units on a scale | Fingolimod | Multiple Sclerosis Disease Modifying Treatments (MS DMTs) |
|---|---|---|
| Change From Baseline in the Patient-reported Side Effects Subscale Using the TSQM v1.4 | 22.9 ± 29.89 | 3.5 ± 23.18 |
The convenience subscale was scored as follows: questions 9 and 10 scored as 1(extremely difficult) to 7 (extremely easy), and question 11 scored as 1(extremely inconvenient) to 7 (extremely convenient). The scores of the domain were added together and an algorithm was used to create a score of 0 to 100. Higher scores indicated greater satisfaction. A positive change from baseline indicates improvement.
| units on a scale | Fingolimod | Multiple Sclerosis Disease Modifying Treatments (MS DMTs) |
|---|---|---|
| Change From Baseline in the Patient-reported Convenience Subscale Using the TSQM v1.4 | 41.8 ± 22.85 | 1.5 ± 18.33 |
The SF-36v2 is a validated health-related quality of life instrument used in numerous disease states, including MS. It is a self-administered survey that measures 8 domains of health including: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems and general mental health. Additionally, two summary scale scores can be calculated: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). If half or more questions within a domain were answered, then a score was calculated for that domain. Otherwise, the patient score for that domain was set to missing. If the patient was missing any 1 of the 8 scale scores, then the physical and mental component scores were set to missing. An algorithm was used to create a score from 0 to 100 for each domain score and component score. A positive change from baseline indicates improvement.
| units on a scale | Fingolimod | Multiple Sclerosis Disease Modifying Treatments (MS DMTs) |
|---|---|---|
| Physical Function (n=745,226) | 1.5 ± 7.96 | 0.4 ± 7.03 |
| Role Limitations d/t Physical Health (n=742,226) | 2.8 ± 9.65 | 1.2 ± 8.51 |
| Bodily Pain (n=742,226) | 2.0 ± 9.7 | -0.3 ± 8.38 |
| General Health Perceptions (n=737,224) | 0.8 ± 8.29 | -0.3 ± 7.24 |
| Vitality (n=745,227) | 2.8 ± 8.88 | 0.6 ± 7.73 |
| Social Functioning (n=747,227) | 2.6 ± 10.31 | 0.8 ± 10.61 |
| Role Limitation d/t Emotional Problems (n=745,226) | 1.6 ± 12.48 | -0.6 ± 11.51 |
| General Mental Health (n=745,227) | 2.2 ± 9.62 | 0.3 ± 9.37 |
| Physical Component Summary Scale (n=724,222) | 1.7 ± 7.41 | 0.3 ± 6.48 |
| Mental Component Summary Scale (n=724,222) | 2.3 ± 10.03 | 0.2 ± 9.62 |
The Beck Depression Inventory (BDI-II) is a 21-question multiple-choice self-report inventory. Each item is scored from 0 to 3. The questions in the BDI-II refer to how the patient has been feeling over the past two weeks specifically. The BDI-II total score was calculated by summing the 21 item scores. Final scores ranged from 0 to 63 where higher scores indicated more severe depression. If no more than 20% of the items were missing, the total score was the product of the mean response of the non-missing items and the total number of items. If more than 20% of all items were missing, the total score was set to missing. A negative change indicates improvement.
| units on a scale | Fingolimod | Multiple Sclerosis Disease Modifying Treatments (MS DMTs) |
|---|---|---|
| Change from Baseline to Month 3 (n=748,236) | -3.2 ± 7.17 | -0.8 ± 6.57 |
| Change from Baseline to Month 6 (n=709,223) | -3.4 ± 7.64 | -0.6 ± 6.76 |
The CGI-I is a rating scale allowing a physician-reported global evaluation of the subject's improvement over time. The Investigator assessed the subject's clinical change relative to the symptoms at baseline on the CGI-I, a seven-point scale, with rating as follows: 1=Very much improved, 2=Much improved, 3=Minimally improved, 4=No change, 5=Minimally worse, 6=Much worse, 7=Very much worse. The assessments were completed at Month 3 and Month 6. A lower score indicates improvement.
| units on a scale | Fingolimod | Multiple Sclerosis Disease Modifying Treatments (MS DMTs) |
|---|---|---|
| Month 3 (n=758,242) | 3.4 ± 1.02 | 3.9 ± 0.72 |
| Month 6 (n=727,228) | 3.2 ± 1.11 | 3.9 ± 0.62 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Fingolimod | — | 31/783 (4%) | 316/783 (40.4%) |
| Standard MS DMT | — | 5/245 (2%) | 51/245 (20.8%) |
| Fingolimod Extension Phase | — | 7/193 (3.6%) | 56/193 (29%) |
| Event | Fingolimod | Standard MS DMT | Fingolimod Extension Phase |
|---|---|---|---|
| Multiple sclerosis relapseNervous system disorders | 5/783 | 2/245 | 0/193 |
| DiarrhoeaGastrointestinal disorders | 0/783 | 0/245 | 1/193 |
| Gastric ileusGastrointestinal disorders | 0/783 | 0/245 | 1/193 |
| NauseaGastrointestinal disorders | 0/783 | 0/245 | 1/193 |
| Small intestinal obstructionGastrointestinal disorders | 0/783 | 0/245 | 1/193 |
| Chest painGeneral disorders | 1/783 | 0/245 | 1/193 |
| ChillsGeneral disorders | 0/783 | 0/245 | 1/193 |
| PainGeneral disorders | 0/783 | 0/245 | 1/193 |
| PyrexiaGeneral disorders | 0/783 | 0/245 | 1/193 |
| GastroenteritisInfections and infestations | 0/783 | 0/245 | 1/193 |
| Event | Fingolimod | Standard MS DMT | Fingolimod Extension Phase |
|---|---|---|---|
| HeadacheNervous system disorders | 97/783 | 8/245 | 19/193 |
| FatigueGeneral disorders | 90/783 | 14/245 | 10/193 |
| Upper respiratory tract infectionInfections and infestations | 51/783 | 8/245 | 9/193 |
| DizzinessNervous system disorders | 50/783 | 7/245 | 7/193 |
| NauseaGastrointestinal disorders | 48/783 | 5/245 | 11/193 |
| NasopharyngitisInfections and infestations | 43/783 | 13/245 | 7/193 |
| HypertensionVascular disorders | 43/783 | 4/245 | 6/193 |
| DiarrhoeaGastrointestinal disorders | 41/783 | 4/245 | 3/193 |
| Age, Continuous(years) | Fingolimod | Multiple Sclerosis Disease Modifying Treatments (MS DMTs) | Total |
|---|---|---|---|
| Mean | 46 ± 9.82 | 45.1 ± 9.82 | 45.8 ± 9.82 |
| Sex: Female, Male(Participants) | Fingolimod | Multiple Sclerosis Disease Modifying Treatments (MS DMTs) | Total |
|---|---|---|---|
| Female | 601 | 208 | 809 |
| Male | 189 | 55 | 244 |
Showing the first 100 of 149 sites across 3 countries. Choose a country and city above to see the rest.
The record gives a start of Aug 2010, a primary completion of Aug 2012 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2013, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fingolimod